Close Menu

NEW YORK – Researchers reported results from a Phase I study comparing AstraZeneca's investigational AKT inhibitor capivasertib alone or in combination with the endocrine therapy fulvestrant in AKT1 E17K-mutated, estrogen receptor-positive metastatic breast cancer patients in Clinical Cancer Research this week.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.